John Mickey
Cardiovascular Disease · Lafayette, LANPI 1710988241
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.4% of the total across 138 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 21 manufacturers, the largest accounting for just 16.2% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $1,131 and has fallen 98.3% since, to $19 in 2023. That places this record below the midpoint for cardiovascular disease clinicians in LA, where the typical reported total is $3,225.
Across 138 payments — averaging $16.51 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novartis$368
- ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$280
- Johnson & Johnson$249
- Pfizer$223
- Kowa Pharmaceuticals America, Inc.$202
- Amgen$171
- plus $785 from 15 others
What the payments were for
- Food & beverage$2,26599%
- Education$141%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novartis | 23 | $368 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 16 | $280 |
| Johnson & Johnson | 18 | $249 |
| Pfizer | 13 | $223 |
| Kowa Pharmaceuticals America, Inc. | 11 | $202 |
| Amgen | 11 | $171 |
| Amarin Pharma, Inc. | 10 | $158 |
| Sanofi-aventis U.S. LLC | 7 | $135 |
| Abiomed | 2 | $107 |
| E.r. Squibb & Sons, L.L.C. | 6 | $81 |
| Regeneron Healthcare Solutions, Inc. | 5 | $71 |
| Arbor Pharmaceuticals, Inc. | 4 | $58 |
| United Therapeutics Corporation | 2 | $30 |
| Boehringer Ingelheim | 2 | $28 |
| Otsuka America Pharmaceutical, Inc. | 2 | $24 |
| Esperion Therapeutics, Inc. | 1 | $19 |
| Gilead | 1 | $18 |
| Medtronic | 1 | $17 |
| Merck | 1 | $17 |
| Boston Scientific | 1 | $12 |
| AstraZeneca | 1 | $11 |
How this compares
$2,279 in reported general payments places this provider in the 40th percentile of 281 cardiovascular disease providers in Louisiana.
Other cardiovascular disease in Lafayette
- Wade MayLafayette$30K
- Corwin ThomasLafayette$30K
- Brent RochonLafayette$21K
- Syed Fazal Ur RehmanLafayette$12K
- Keith FerdinandNew Orleans$239K
- Carl LavieNew Orleans$228K
- Imran ChaudryMonroe$202K
- Corey FosterLake Charles$158K
- George KaramBaton Rouge$110K
- Harry HawthorneAlexandria$89K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.